Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis

AcnePsoriasis

Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study

J Eur Acad Dermatol Venereol

Motedayen Aval L, Yiu ZZN, Alabas OA, Griffiths CEM, Reynolds NJ, Hampton PJ, Smith CH, Warren RB, BADBIR Study Group

doi: 10.1111/jdv.20739

Psoriasis

Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study

J Eur Acad Dermatol Venereol

Miao Y, Beauchet A, Piram M, McPherson T, Torres T, Yesli Y, Aubert H, Bodemer C, Bertoli C, Tardieu M, Hubiche T, Bonniaud B, Neri I, Chessa MA, Lasek A, Prignano F, Barbarot S, Bursztejn AC, Leducq S, Sergeant M, Puzenat E, Chiaverini C, Sigg N, Mallet S, Miquel J, Pourchot D, Patel KX, Burden-Teh E, Flohr C, Di Lernia V, Mahé E, GrPso of the Société Française de Dermatologie; Groupe de Recherche de la Société Française de Dermatologie Pédiatrique

doi: 10.1111/jdv.70108

Psoriasis

Residual Inflammation in Patients with Psoriasis Treated with Biologic Therapy: Findings from 3 Prospective Observational Cohorts

J Invest Dermatol

Lecumberri A, Berna-Rico E, Gelfand JM, Svedbom A, Abbad-Jaime de Aragón C, Neria F, Monge D, Ballester-Martínez A, Pindado-Ortega C, Castellanos-González M, Llamas-Velasco M, Barderas MG, Solís J, Fernández-Friera L, Jaén P, Stahle M, Mehta NN, González-Cantero Á

doi: 10.1016/j.jid.2025.03.014

Further Publications Rheumatology

Biologic disease-modifying antirheumatic drugs survival in late-onset axial spondyloarthritis-data from a Portuguese registry

Rheumatology (Oxford)

Silva SP, Monteiro B, Pinto Oliveira C, Pereira da Costa R, Matos CO, Lopes MD, Gomes CM, Bernardes M, Santos ME, Gago L, Abreu C, Fraga V, Mendes B, Lucas Rocha M, Soares CD, Silva C, Santos H, Valente P, Silva L, Eugénio G, Barcelos A

doi: 10.1093/rheumatology/keaf176

Allergic Diseases

Omalizumab dosing patterns and drug survival in adult patients with chronic spontaneous urticaria

J Eur Acad Dermatol Venereol

Zhang DG, Nielsen ML, Sørensen JA, Naassan S, Vestergaard C, Kocatürk E, Ali Z, Thyssen JP, Egeberg A, Thomsen SF

doi: 10.1111/jdv.20737

Rheumatoid Arthritis

Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease modifying antirheumatic drugs: results from the BIOBADASER III registry

Rheumatology (Oxford)

Molina-Collada J, Otero-Varela L, Vela P, Manrique S, Erausquin C, Campos C, Manero J, Calvo J, Expósito L, García González J, Ruiz Montesinos MD, Rabadán E, Varela AM, Vilamajo IR, Colazo Burlato M, Plasencia C, Sánchez-Alonso F, Castrejón I, BIOBADASER Project Collaborative Group

doi: 10.1093/rheumatology/keaf556

Rheumatoid Arthritis

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug

Arthritis Care Res (Hoboken)

Xie F, Beukelman T, McCormick NP, Curtis JR

doi: 10.1002/acr.80010

Rheumatoid Arthritis

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Arthritis Rheumatol

Aymon R, Mongin D, Guemara R, Salis Z, Askling J, Choquette D, Codreanu C, Di Giuseppe D, Flouri I, Huschek D, Hyrich KL, Iannone F, Kvien TK, Leeb BF, Nordström D, Otero-Varela L, Pavelka K, Pombo-Suarez M, Rodrigues A, Rotar Z, Sidiropoulos P, Provan SA, Strangfeld A, Nina T, Zavada J, Kearsley-Fleet L, Courvoisier DS, Finckh A, Lauper K

doi: 10.1002/art.43188

Psoriasis

Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors

J Am Acad Dermatol

Blauvelt A, Strober BE, Eakin GS, McCormick Howard L, Langan C, van de Kerkhof PCM, Puig L, Lebwohl MG, Romiti R, Armstrong AW, Choon SE, Ramessur R, Gelfand JM, Merola JF, Winthrop KL, Torres T

doi: 10.1016/j.jaad.2025.11.033

Related content

Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study

Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study

Residual Inflammation in Patients with Psoriasis Treated with Biologic Therapy: Findings from 3 Prospective Observational Cohorts

Biologic disease-modifying antirheumatic drugs survival in late-onset axial spondyloarthritis-data from a Portuguese registry

Omalizumab dosing patterns and drug survival in adult patients with chronic spontaneous urticaria

Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease modifying antirheumatic drugs: results from the BIOBADASER III registry

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors